Publication Name	World Journal of Gastroenterology
Manuscript ID	117500
Country	China

Category	Infectious Diseases
Manuscript Type	Retrospective Study
Article Title	Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B
Manuscript Source	Unsolicited Manuscript
All Author List	Hui-Bin Ning, Hui-Ming Jin, Zhen Peng, Kuan Li and Jia Shang
Funding Agency and Grant Number
Corresponding Author	Jia Shang, Chief Physician, Department of Infectious Diseases, Henan Provincial People's Hospital, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450000, Henan Province, China. shangjia666@126.com
Key Words	Chronic hepatitis B; Entecavir; Tenofovir alafenamide fumarate; Bone safety; Renal safety
Core Tip	Nucleoside/nucleotide analogs are currently the core drugs for the antiviral treatment of chronic hepatitis B (CHB). Among them, entecavir and tenofovir alafenamide fumarate (TAF) are recommended as first-line treatment regimens in domestic and international guidelines due to their potent antiviral activity and low resistance rates. However, direct comparative data between TAF and entecavir remain limited, particularly in long-term follow-up studies of Chinese CHB populations. The long-term differences in bone and renal safety between TAF and entecavir warrant further investigation. Therefore, this study aims to provide critical insights for optimizing individualized treatment strategies for CHB by comparing the clinical efficacy and safety profiles of entecavir and TAF.
Citation	Ning HB, Jin HM, Peng Z, Li K, Shang J. Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B. World J Gastroenterol 2026; In press

Received	2026-01-06 09:18
Peer-Review Started	2026-01-06 09:19
First Decision by Editorial Office Director	2026-01-19 08:52
Return for Revision	2026-01-19 08:52
Revised	2026-01-29 14:59
Publication Fee Transferred	2026-02-02 00:49
Second Decision by Editor	2026-03-17 03:07
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-03-17 10:07
Articles in Press	2026-03-17 10:07
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com